Jubilant Pharmova Limited

JUBLPHARMA

INE700A01033

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:51 16/07/2024 pm IST			5-day change	1st Jan Change
739.4 ^INR	+2.38%		-0.98%	+35.47%

25/06	Jubilant Pharmova Arm Completes Prepayment of $75 Million Term Loan	MT
18/06	Jubilant Pharmova Gets 15 Observations from US FDA for Unit's Manufacturing Facility in Canada; Shares Dip 3%	MT

Jubilant Life Sciences Limited Appoints Rajiv Shah as Company Secretary & Compliance Officer

February 20, 2015

Jubilant Life Sciences Limited announced that Mr. Rajiv Shah has been appointed as Company Secretary of the company with effect from February 16, 2015. He shall also be the Compliance officer of the Company.

Latest news about Jubilant Pharmova Limited

Jubilant Pharmova Arm Completes Prepayment of $75 Million Term Loan	25/06	MT
Jubilant Pharmova Gets 15 Observations from US FDA for Unit's Manufacturing Facility in Canada; Shares Dip 3%	18/06	MT
Jubilant Pharmova Unit to Prepay $75 Million Term Loan	17/06	MT
Jubilant Pharma Unit to Invest $50 Million for PET Radiopharmacy Network Expansion in US	17/06	MT
Jubilant Pharmova Gets Three US FDA Observations for Unit's Facility in Washington; Shares Drop 3%	10/06	MT
Jubilant Pharmova Narrows Loss in Fiscal Q4	30/05	MT
India's Jubilant Pharmova reports narrower fourth-quarter loss	29/05	RE
Jubilant Pharmova Limited Announces Resignation of Jinang Pratap Parekh as Whole-Time Director, Effective May 31, 2024	29/05	CI
Jubilant Pharmova Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024	29/05	CI
Jubilant Pharmova Limited Reports Earnings Results for the Full Year Ended March 31, 2024	29/05	CI
Jubilant Pharmova Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	29/05	CI
Jubilant Pharmova Appoints CEO for Radiopharma Business	03/05	MT
Jubilant Pharmova Limited Receives Rectification Application Against Certain Tax Demands Raised by the Income Tax Department for Assessment Year 2015- 16	30/04	CI
Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA	25/04	MT
Jubilant Pharmova Unit Gets VAI Status for Roorkee, India Facility	17/04	MT
India's Jubilant Pharmova posts quarterly profit	02/02	RE
Jubilant Pharmova Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	02/02	CI
Jubilant Ingrevia Redeems INR1 Billion at Maturity Date	15/11	MT
Jubilant Pharmova Unit Gets US FDA's Approval for Technetium Sulfur Colloid Injection	13/11	MT
Jubilant Pharmova Limited Announces the Resignation of Kumar Ramamurthi as Director and Whole-Time Director, Effective October 31, 2023	27/23/27	CI
Jubilant Pharmova Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	27/23/27	CI
Domino's India operator Jubilant beats Q2 profit estimates on cheaper launches	25/23/25	RE
Jubilant Pharmova Limited Recommends Dividend for the Year Ended March 31, 2023, Payable on or Before September 29, 2023	08/23/08	CI
Jubilant Pharmova Limited Recommends Dividend for the Financial Year Ended March 31, 2023	31/23/31	CI
Jubilant Pharmova's Consolidated Profit Plunges in Fiscal Q1	20/23/20	MT

Chart Jubilant Pharmova Limited

Duration

Period

More charts

Company Profile

Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Companyâs segments include Radiopharma, Allergy Immunotherapy, Contract Development and Manufacturing Organisation-Sterile Injectables, Generics, Contract Research, Development and Manufacturing Organisation, Proprietary Novel Drugs, and Management Services. The Radiopharma segment comprises radiopharmaceuticals including radio pharmacies. The Contract Development and Manufacturing Organisation-Sterile Injectables segment includes contract development and manufacturing organisation-sterile injectables products. The Generics segment includes solid dosage formulations. The Contract Research, Development and Manufacturing Organisation segment includes drug discovery services, and active pharmaceutical ingredients. The Proprietary Novel Drugs segment includes patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.

Sector

Pharmaceuticals

Calendar

18/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

739.4 INR

Average target price

871 INR

Spread / Average Target

+17.81%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JUBILANT PHARMOVA LIMITED	+35.47%	1.37B
ELI LILLY AND COMPANY	+61.50%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-3.89%	359B
MERCK & CO., INC.	+15.40%	325B
ABBVIE INC.	+9.05%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.93%	177B
PFIZER, INC.	+2.26%	165B

Other Pharmaceuticals

Jubilant Pharmova Limited

Equities

JUBLPHARMA

INE700A01033

Pharmaceuticals

Jubilant Life Sciences Limited Appoints Rajiv Shah as Company Secretary & Compliance Officer

Latest news about Jubilant Pharmova Limited

Chart Jubilant Pharmova Limited

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals